期刊
NATURE REVIEWS MICROBIOLOGY
卷 12, 期 4, 页码 289-299出版社
NATURE PORTFOLIO
DOI: 10.1038/nrmicro3230
关键词
-
类别
资金
- US National Institutes of Heath (NIH)
- US National Institute of Allergy and Infectious Diseases (NIAID) [R21AI100766, R01AI085669, R01AI098637, R01AI106725]
Clinical trials of vaccines against Mycobacterium tuberculosis are well under way and results are starting to come in. Some of these results are not so encouraging, as exemplified by the latest Aeras-422 and MVA85A trials. Other than empirically determining whether a vaccine reduces the number of cases of active tuberculosis, which is a daunting prospect given the chronic nature of the disease, we have no way of assessing vaccine efficacy. Therefore, investigators seek to identify biomarkers that predict vaccine efficacy. Historically, focus has been on the production of interferon-gamma by CD4(+) T cells, but this has not been a useful correlate of vaccine-induced protection. In this Opinion article, we discuss recent advances in our understanding of the immune control of M. tuberculosis and how this knowledge could be used for vaccine design and evaluation.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据